HER2+ Breast Cancer | Specialty

Evolving Landscape of HER2-Targeted Therapy in Breast Cancer

January 11th 2020

Dr. Hamilton on the HER2CLIMB Trial in Metastatic HER2+ Breast Cancer

January 10th 2020

Erika P. Hamilton, MD, director, Breast Cancer and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the phase II HER2CLIMB trial in metastatic HER2-positive breast cancer.

Dr. Vidal on the Use of CDK4/6 Inhibitors in HER2+ Breast Cancer

January 4th 2020

Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential use of CDK4/6 inhibitors in HER2-positive breast cancer.

Current Advancements in HER2+ Breast Cancer Management

December 24th 2019

HER2CLIMB-02 Trial Regimen Toxicities and Impact

December 24th 2019

The HER2CLIMB-02 Trial Design, Results and Implications

December 24th 2019

HER2+ Breast Cancer: Brain Metastasis Prevalence & Later-Line Therapy

December 24th 2019

Emerging Data for the Treatment of HER2+ mBC

December 24th 2019

HER2+ mBC: Systemic Therapies and HER2CLIMB-02 Trial

December 24th 2019

Management of CNS Metastases in R/R HER2+ mBC

December 24th 2019

HER2+ Metastatic Breast Cancer: Standard of Care Therapies

December 24th 2019

FDA Approval Sought for Tucatinib in HER2+ Breast Cancer

December 23rd 2019

A new drug application has been submitted to the FDA for tucatinib for use in combination with trastuzumab and capecitabine for the treatment of patients with unresectable locally advanced or metastatic HER2-positive breast cancer.

Dr. Traina on the FDA Approval of Trastuzumab Deruxtecan for HER2+ Breast Cancer

December 21st 2019

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) for patients with HER2-positive, locally advanced, or metastatic breast cancer who have been treated with trastuzumab (Herceptin) and pertuzumab (Perjeta) and have disease progression after ado-trastuzumab emtansine (T-DM1; Kadcyla).

FDA Approves Trastuzumab Deruxtecan for HER2+ Breast Cancer

December 21st 2019

The FDA has granted an accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ≥2 prior anti–HER2-based regimens in the metastatic setting.

FDA Approval Sought for Margetuximab in HER2+ Metastatic Breast Cancer

December 20th 2019

A biologics license application has been submitted to the FDA for margetuximab for use in combination with chemotherapy as a treatment for patients with metastatic HER2-positive breast cancer.

Adjuvant T-DM1 Approved in Europe for HER2+ Early Breast Cancer

December 19th 2019

The European Commission has approved ado-trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease (breast and/or lymph nodes) following neoadjuvant taxane-based chemotherapy and HER2-targeted therapy.

Dr. Hart on Antibody-Drug Conjugates in HER2+ Breast Cancer

December 19th 2019

Lowell L. Hart, MD, FACP, discusses the utility of antibody-drug conjugates in HER2-positive breast cancer.

FDA Grants Tucatinib Breakthrough Designation for HER2+ Breast Cancer

December 18th 2019

The FDA has granted tucatinib a breakthrough therapy designation for use in combination with trastuzumab and capecitabine for the treatment of patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including patients with brain metastases, who had prior trastuzumab, pertuzumab, and ado-trastuzumab emtansine.

Talking Tumors: Weill Cornell Medicine Experts Walk Through Challenging Breast Cancer Cases

December 18th 2019

Lisa Newman, MD, MPH, FACS, FASCO, and Alan B. Astrow, MD, discuss the need for systemic therapy in women with microinvasive triple-negative breast cancer and more intensive adjuvant therapy in women with intermediate-risk hormone receptor-positive, HER2-negative breast cancer.

Dr. Lin on Impact of Neratinib on CNS Metastases in HER2+ Breast Cancer

December 13th 2019

Nancy Lin, MD, discusses the impact of neratinib on development and progression of central nervous system metastases in patients with HER2-positive metastatic breast cancer.